-
1
-
-
84887942578
-
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
-
3843585 24261963
-
Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 88
-
-
Akinleye, A.1
Avvaru, P.2
Furqan, M.3
Song, Y.4
Liu, D.5
-
2
-
-
84883160397
-
Ibrutinib and novel BTK inhibitors in clinical development
-
1:CAS:528:DC%2BC3sXhsVagtrjI 3751776 23958373
-
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 59
-
-
Akinleye, A.1
Chen, Y.2
Mukhi, N.3
Song, Y.4
Liu, D.5
-
3
-
-
84876249574
-
MEK and the inhibitors: From bench to bedside
-
1:CAS:528:DC%2BC3sXmvFejurg%3D 3626705 23587417
-
Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 27
-
-
Akinleye, A.1
Furqan, M.2
Mukhi, N.3
Ravella, P.4
Liu, D.5
-
4
-
-
84889058668
-
STAT inhibitors for cancer therapy
-
4029528 24308725
-
Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):90.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 90
-
-
Furqan, M.1
Akinleye, A.2
Mukhi, N.3
Mittal, V.4
Chen, Y.5
Liu, D.6
-
5
-
-
85064289101
-
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
-
Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013;1(1):5.
-
(2013)
Biomarker Res
, vol.1
, Issue.1
, pp. 5
-
-
Furqan, M.1
Mukhi, N.2
Lee, B.3
Liu, D.4
-
6
-
-
84876953788
-
B-Raf and the inhibitors: From bench to bedside
-
1:CAS:528:DC%2BC3sXotFWrsLw%3D 3646677 23617957
-
Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):30.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 30
-
-
Huang, T.1
Karsy, M.2
Zhuge, J.3
Zhong, M.4
Liu, D.5
-
7
-
-
84875359668
-
Targeting p53 by small molecules in hematological malignancies
-
1:CAS:528:DC%2BC3sXmsFGmsLY%3D 3614876 23531342
-
Saha M, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):23.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 23
-
-
Saha, M.1
Qiu, L.2
Chang, H.3
-
8
-
-
84925221855
-
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
-
1:CAS:528:DC%2BC2MXisFGqsrg%3D 4348009 25482239
-
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-9.
-
(2015)
N Engl J Med
, vol.372
, Issue.4
, pp. 311-319
-
-
Ansell, S.M.1
Lesokhin, A.M.2
Borrello, I.3
Halwani, A.4
Scott, E.C.5
Gutierrez, M.6
Schuster, S.J.7
Millenson, M.M.8
Cattry, D.9
Freeman, G.J.10
Rodig, S.J.11
Chapuy, B.12
Ligon, A.H.13
Zhu, L.14
Grosso, J.F.15
Kim, S.Y.16
Timmerman, J.M.17
Shipp, M.A.18
Armand, P.19
-
9
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
26028407
-
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New Eng J Med. 2015;373(2):123-35.
-
(2015)
The New Eng J Med
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
Crino, L.4
Eberhardt, W.E.5
Poddubskaya, E.6
Antonia, S.7
Pluzanski, A.8
Vokes, E.E.9
Holgado, E.10
Waterhouse, D.11
Ready, N.12
Gainor, J.13
Aren Frontera, O.14
Havel, L.15
Steins, M.16
Garassino, M.C.17
Aerts, J.G.18
Domine, M.19
Paz-Ares, L.20
Reck, M.21
Baudelet, C.22
Harbison, C.T.23
Lestini, B.24
Spigel, D.R.25
more..
-
10
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
25891174
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
Patnaik, A.7
Aggarwal, C.8
Gubens, M.9
Horn, L.10
Carcereny, E.11
Ahn, M.J.12
Felip, E.13
Lee, J.S.14
Hellmann, M.D.15
Hamid, O.16
Goldman, J.W.17
Soria, J.C.18
Dolled-Filhart, M.19
Rutledge, R.Z.20
Zhang, J.21
Lunceford, J.K.22
Rangwala, R.23
Lubiniecki, G.M.24
Roach, C.25
Emancipator, K.26
Gandhi, L.27
more..
-
11
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
26027431
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
Schadendorf, D.7
Dummer, R.8
Smylie, M.9
Rutkowski, P.10
Ferrucci, P.F.11
Hill, A.12
Wagstaff, J.13
Carlino, M.S.14
Haanen, J.B.15
Maio, M.16
Marquez-Rodas, I.17
McArthur, G.A.18
Ascierto, P.A.19
Long, G.V.20
Callahan, M.K.21
Postow, M.A.22
Grossmann, K.23
Sznol, M.24
Dreno, B.25
Bastholt, L.26
Yang, A.27
Rollin, L.M.28
Horak, C.29
Hodi, F.S.30
more..
-
12
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
25891304
-
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-17.
-
(2015)
N Engl J Med
, vol.372
, Issue.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
Robert, C.4
Grossmann, K.5
McDermott, D.6
Linette, G.P.7
Meyer, N.8
Giguere, J.K.9
Agarwala, S.S.10
Shaheen, M.11
Ernstoff, M.S.12
Minor, D.13
Salama, A.K.14
Taylor, M.15
Ott, P.A.16
Rollin, L.M.17
Horak, C.18
Gagnier, P.19
Wolchok, J.D.20
Hodi, F.S.21
more..
-
13
-
-
84884698526
-
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
-
3851976 24283718
-
Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6(1):74.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 74
-
-
Shi, L.1
Chen, S.2
Yang, L.3
Li, Y.4
-
14
-
-
84894552888
-
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
-
1:CAS:528:DC%2BC2cXlt1ems74%3D 24401022
-
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-10.
-
(2014)
N Engl J Med
, vol.370
, Issue.12
, pp. 1101-1110
-
-
Goede, V.1
Fischer, K.2
Busch, R.3
Engelke, A.4
Eichhorst, B.5
Wendtner, C.M.6
Chagorova, T.7
De La Serna, J.8
Dilhuydy, M.S.9
Illmer, T.10
Opat, S.11
Owen, C.J.12
Samoylova, O.13
Kreuzer, K.A.14
Stilgenbauer, S.15
Dohner, H.16
Langerak, A.W.17
Ritgen, M.18
Kneba, M.19
Asikanius, E.20
Humphrey, K.21
Wenger, M.22
Hallek, M.23
more..
-
15
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
1:CAS:528:DC%2BC3cXhtl2gsbbE 21047225
-
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21.
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1812-1821
-
-
Younes, A.1
Bartlett, N.L.2
Leonard, J.P.3
Kennedy, D.A.4
Lynch, C.M.5
Sievers, E.L.6
Forero-Torres, A.7
-
16
-
-
84860744403
-
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
-
1:CAS:528:DC%2BC38Xnt1Gjsrw%3D 22571200
-
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
-
(2012)
N Engl J Med
, vol.366
, Issue.19
, pp. 1759-1769
-
-
Palumbo, A.1
Hajek, R.2
Delforge, M.3
Kropff, M.4
Petrucci, M.T.5
Catalano, J.6
Gisslinger, H.7
Wiktor-Jedrzejczak, W.8
Zodelava, M.9
Weisel, K.10
Cascavilla, N.11
Iosava, G.12
Cavo, M.13
Kloczko, J.14
Blade, J.15
Beksac, M.16
Spicka, I.17
Plesner, T.18
Radke, J.19
Langer, C.20
Ben Yehuda, D.21
Corso, A.22
Herbein, L.23
Yu, Z.24
Mei, J.25
Jacques, C.26
Dimopoulos, M.A.27
more..
-
17
-
-
84927150740
-
Immune checkpoint blockade in cancer therapy
-
25605845
-
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-82.
-
(2015)
J Clin Oncol
, vol.33
, Issue.17
, pp. 1974-1982
-
-
Postow, M.A.1
Callahan, M.K.2
Wolchok, J.D.3
-
18
-
-
84879813079
-
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: Progress and challenges
-
1:CAS:528:DC%2BC3sXht1ajurvF 3706354 23829929
-
Han E, Li X-l, Wang C-R, Li T-F, Han S-Y. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013;6(1):47.
-
(2013)
J Hematol Oncol
, vol.6
, Issue.1
, pp. 47
-
-
Han, E.1
Li, X.-L.2
Wang, C.-R.3
Li, T.-F.4
Han, S.-Y.5
-
19
-
-
84926099033
-
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study
-
1:CAS:528:DC%2BC2MXht1yhsb0%3D 25524800
-
Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.
-
(2015)
Lancet Oncol
, vol.16
, Issue.1
, pp. 57-66
-
-
Topp, M.S.1
Gokbuget, N.2
Stein, A.S.3
Zugmaier, G.4
O'Brien, S.5
Bargou, R.C.6
Dombret, H.7
Fielding, A.K.8
Heffner, L.9
Larson, R.A.10
Neumann, S.11
Foa, R.12
Litzow, M.13
Ribera, J.M.14
Rambaldi, A.15
Schiller, G.16
Bruggemann, M.17
Horst, H.A.18
Holland, C.19
Jia, C.20
Maniar, T.21
Huber, B.22
Nagorsen, D.23
Forman, S.J.24
Kantarjian, H.M.25
more..
-
20
-
-
84938506999
-
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells
-
25875246
-
Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
-
(2015)
MAbs
, vol.7
, Issue.3
, pp. 584-604
-
-
Reusch, U.1
Duell, J.2
Ellwanger, K.3
Herbrecht, C.4
Knackmuss, S.H.5
Fucek, I.6
Eser, M.7
McAleese, F.8
Molkenthin, V.9
Gall, F.L.10
Topp, M.11
Little, M.12
Zhukovsky, E.A.13
-
21
-
-
84978025178
-
Ibrutinib for B cell malignancies
-
3913970 24472371
-
Novero A, Ravella P, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3(1):4.
-
(2014)
Exp Hematol Oncol
, vol.3
, Issue.1
, pp. 4
-
-
Novero, A.1
Ravella, P.2
Chen, Y.3
Dous, G.4
Liu, D.5
-
22
-
-
84933505755
-
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
-
25887777
-
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024-31.
-
(2015)
Blood
, vol.125
, Issue.26
, pp. 4024-4031
-
-
Rothe, A.1
Sasse, S.2
Topp, M.S.3
Eichenauer, D.A.4
Hummel, H.5
Reiners, K.S.6
Dietlein, M.7
Kuhnert, G.8
Kessler, J.9
Buerkle, C.10
Ravic, M.11
Knackmuss, S.12
Marschner, J.-P.13
Pogge Von Strandmann, E.14
Borchmann, P.15
Engert, A.16
-
23
-
-
0033545963
-
Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity
-
1:CAS:528:DyaK1MXjtFCntL4%3D 21913 10318937
-
Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A. 1999;96(10):5640-4.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, Issue.10
, pp. 5640-5644
-
-
Mandelboim, O.1
Malik, P.2
Davis, D.M.3
Jo, C.H.4
Boyson, J.E.5
Strominger, J.L.6
-
24
-
-
0027358685
-
A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo
-
1:CAS:528:DyaK2cXhtlWrsLY%3D 8244580
-
Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 1993;55(5):830-6.
-
(1993)
Int J Cancer
, vol.55
, Issue.5
, pp. 830-836
-
-
Hombach, A.1
Jung, W.2
Pohl, C.3
Renner, C.4
Sahin, U.5
Schmits, R.6
Wolf, J.7
Kapp, U.8
Diehl, V.9
Pfreundschuh, M.10
-
25
-
-
0034783024
-
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines
-
1:CAS:528:DC%2BD3MXlslaltb0%3D
-
Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clinical Cancer Res. 2001;7(7):1873-81.
-
(2001)
Clinical Cancer Res
, vol.7
, Issue.7
, pp. 1873-1881
-
-
Hartmann, F.1
Renner, C.2
Jung, W.3
Da Costa, L.4
Tembrink, S.5
Held, G.6
Sek, A.7
Konig, J.8
Bauer, S.9
Kloft, M.10
Pfreundschuh, M.11
-
26
-
-
0030974954
-
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
-
1:CAS:528:DyaK2sXhvVarsrc%3D 9058726
-
Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;89(6):2042-7.
-
(1997)
Blood
, vol.89
, Issue.6
, pp. 2042-2047
-
-
Hartmann, F.1
Renner, C.2
Jung, W.3
Deisting, C.4
Juwana, M.5
Eichentopf, B.6
Kloft, M.7
Pfreundschuh, M.8
-
27
-
-
84899744468
-
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
-
24670809
-
Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014;6(3):728-39.
-
(2014)
MAbs
, vol.6
, Issue.3
, pp. 728-739
-
-
Reusch, U.1
Burkhardt, C.2
Fucek, I.3
Le Gall, F.4
Le Gall, M.5
Hoffmann, K.6
Knackmuss, S.H.7
Kiprijanov, S.8
Little, M.9
Zhukovsky, E.A.10
-
28
-
-
0027197493
-
"Diabodies": Small bivalent and bispecific antibody fragments
-
1:CAS:528:DyaK3sXltlOjur8%3D 46948 8341653
-
Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90(14):6444-8.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, Issue.14
, pp. 6444-6448
-
-
Holliger, P.1
Prospero, T.2
Winter, G.3
-
29
-
-
84938628792
-
Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
-
in press
-
Wu J, J Fu, M Zhang, Liu D: Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015, 8:in press.
-
(2015)
J Hematol Oncol
, vol.8
-
-
Wu, J.1
Fu, J.2
Zhang, M.3
Liu, D.4
-
30
-
-
84913588010
-
Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics
-
25517309
-
Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, et al. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. MAbs. 2014;6(5):1243-54.
-
(2014)
MAbs
, vol.6
, Issue.5
, pp. 1243-1254
-
-
Asano, R.1
Shimomura, I.2
Konno, S.3
Ito, A.4
Masakari, Y.5
Orimo, R.6
Taki, S.7
Arai, K.8
Ogata, H.9
Okada, M.10
Furumoto, S.11
Onitsuka, M.12
Omasa, T.13
Hayashi, H.14
Katayose, Y.15
Unno, M.16
Kudo, T.17
Umetsu, M.18
Kumagai, I.19
|